Covid-19 roundup: After winning an EUA, GSK and Vir are back with full data on their monoclonal antibody; New Zealand authorizes Pfizer/BioNTech vaccine for kids as young as 12
A few weeks after snagging an emergency use authorization for their monoclonal antibody sotrovimab based on interim data, GSK and Vir Biotechnology are back with confirmatory results to support the drug’s use in non-hospitalized Covid-19 patients.
Sotrovimab reduced hospitalization of more than 24 hours or death by 79% at Day 29 compared to placebo, the partners said on Monday. The primary analysis was based on 1,057 patients with mild to moderate Covid-19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.